Navigation Links
Joint pain in children: Is it just a sore knee, or ... ?
Date:3/2/2011

While lab tests and imaging can sometimes help diagnose juvenile idiopathic arthritis (JIA), a physical examination and thorough patient history are the most valuable tools in identifying this disease. According to a new literature review from the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), the rate of false positives in laboratory evaluations and imaging studies meant to screen for juvenile arthritis makes their value limited.

Juvenile idiopathic arthritis (formerly known as juvenile rheumatoid arthritis) is an autoimmune disease that affects nearly 300,000 children in the United States under the age of 18. The cause is not known, and it does not appear to be genetic, although some family members may suffer from other autoimmune disorders. Symptoms may include:

  • joint stiffness in the morning that improves later in the day;
  • pain, swelling, and tenderness in the joints;
  • limping or limits in range of motion;
  • high fever and light rash;
  • weight loss;
  • fatigue or irritability; and/or
  • red eyes or blurred vision.

Depending on the type of JIA, these symptoms can vary quite a bit. In fact, some young patients may not suffer any of these symptoms, but have a swollen joint that is discovered after another incident such as an injury.

"To establish a diagnosis of juvenile idiopathic arthritis is a matter of pattern recognition," says Marilynn Punaro, MD, a pediatric rheumatologist at Texas Scottish Rite Hospital for Children and University of Texas Southwestern Medical Center, Dallas, TX, and the author of this review. "Also, there is no lab test that can conclusively diagnose rheumatic diseaseyou have to rule out other common diagnoses. That is why a full physical exam is important, as well as a detailed patient history that will reveal other symptoms. If the patient has one swollen joint, the other joints should be examined because the diagnoses could be very different based on what is found in that exam."

Review details and findings:

  • If JIA is suspected, the orthopaedic surgeon should conduct an assessment of all peripheral joints, not just the joint or joints about which the patient is complaining.
  • Exquisitely painful, tender, or red joints are not typically diagnostic for JIA.
  • Oligoarticular JIA (where just a few joints are affected) is the most common type of JIA, affecting 60 percent of children with this disorder. The onset of this type of arthritis is usually between the ages of 1 and 3.
  • Treatment of juvenile arthritis is designed to reduce swelling, maintain full movement of affected joints, and relieve pain, and includes medications and physical therapy. Surgery may be indicated in rare cases. Some JIA patients' disease can go into remission.
  • Recent clinical trials are showing that with new drug treatments, remission will soon be a realistic goal for most patients.

"It is important to try and diagnose JIA early so treatment can begin," Punaro says. "If left untreated for months or years, there is a likelihood of long-term disability, growth problems or deformity. The disease can cause joint damage that is irreversible. The good news, though, is that when we do diagnose JIA, we have many excellent treatments available."


'/>"/>

Contact: Lauren Pearson
pearson@aaos.org
847-384-4031
American Academy of Orthopaedic Surgeons
Source:Eurekalert

Related medicine news :

1. LA BioMed and CellSeed to launch joint research project on regenerative medicine technology
2. Inexpensive rinsing effective at reducing post-op infection following joint replacement surgery
3. NYU Langone Department of Orthopaedic Surgery chosen to participate in joint replacement registry
4. Biological joints could replace artificial joints soon
5. U.S. Needs National Registry for Joint Replacement Devices: Study
6. Painful Knees Often Tied to Pain in Other Joints
7. Study sheds light on aromatase inhibitor joint pain syndrome
8. Joint pain linked to breast cancer drug not inflammatory arthritis or autoimmune disease
9. NTU and A*STAR launch joint Ph.D. research program in immunology
10. U-M Medical School creates joint institute with Peking University
11. More Evidence That Glucosamine, Chondroitin Wont Help Ailing Joints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... ... April 22, 2017 , ... Ecommerce sales have grown every year since ... $394.9 billion. The consequences of rapid innovation and growth are often neglected in ... it is every business and individual’s job to give something back to the planet ...
(Date:4/22/2017)... ... April 22, 2017 , ... The San Juan Capistrano summer camp team ... report outlining the need for summer camps to provide physical activities for all campers. To ... Activity In Summer Camps , With an increase in specialty camps that focus on what ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... Salas-Wright finds that youth violence is declining—and at noteworthy rates. Between 2002 and ... of young people involved in violence in the United States. The study, ...
(Date:4/21/2017)... ... April 21, 2017 , ... Young Asset ... services to communities throughout the greater Pittsburgh metropolitan region, is joining forces with ... adaptive bicycles for differently-abled children. , Variety the Children’s Charity is a national ...
(Date:4/21/2017)... ... April 21, 2017 , ... The VIA Agency , ... for Theravent, Inc. , the makers of a revolutionary new device clinically ... is now working to expand distribution in anticipation of a national launch. VIA ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and ... today announced the signing of a three-year exclusive ... will deploy a dedicated sales team to introduce ... U.S., primarily focused in 13 states in the ...
Breaking Medicine Technology: